AstraZeneca expects mid- to high-single-digit revenue growth and low double-digit profit expansion in 2026, building on an 8% sales increase and 11% earnings jump in 2025. The pharmaceutical giant’s fourth-quarter results matched analyst forecasts, with core earnings of $2.12 per share and revenue edging up 2% to $15.50 billion.

Cancer drug sales surged 20% to $7.03 billion last quarter, offsetting a 6% decline in cardiovascular treatments pressured by generic competition. CEO Pascal Soriot highlighted 16 successful Phase 3 trials in 2025 and a portfolio of 16 blockbuster medicines, signaling robust research productivity.

Morgan Stanley analysts called the results "good enough," noting the guidance implies a modest 2% boost to revenue estimates. However, they flagged potential investor focus on 2026 operating margins as earnings projections face a slight downward revision. The mixed performance underscores AstraZeneca’s reliance on oncology innovations amid competitive pressures elsewhere.